Literature DB >> 22398321

IL-36 in psoriasis.

J E Towne1, J E Sims.   

Abstract

Psoriasis is a common but severe skin disease with significant health consequences, both physical and psychological. Evidence has emerged during the past several years pointing to a key role for IL-36 in psoriasis. Overexpression of IL-36 in mouse skin leads to a disease quite similar to human plaque psoriasis, and inhibition of IL-36 in human psoriatic skin ameliorates the inflammation. Loss of the natural antagonist of IL-36, IL-36Ra, results in a different, more severe skin disease known as pustular psoriasis. These effects are likely a consequence of the actions of IL-36 both on cells of the immune system as well as on components of skin including fibroblasts and keratinocytes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398321     DOI: 10.1016/j.coph.2012.02.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  58 in total

1.  Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

Authors:  James DeVoti; Lynda Hatam; Alexandra Lucs; Ali Afzal; Allan Abramson; Bettie Steinberg; Vincent Bonagura
Journal:  Mol Med       Date:  2014-08-28       Impact factor: 6.354

2.  E3 Ubiquitin Ligase RNF125 Activates Interleukin-36 Receptor Signaling and Contributes to Its Turnover.

Authors:  Siddhartha S Saha; Gary Caviness; Guanghui Yi; Ernest L Raymond; M Lamine Mbow; C Cheng Kao
Journal:  J Innate Immun       Date:  2017-11-25       Impact factor: 7.349

Review 3.  Immune responses and therapeutic options in psoriasis.

Authors:  Inna S Afonina; Elien Van Nuffel; Rudi Beyaert
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 4.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Authors:  Michelle A Lowes; Chris B Russell; David A Martin; Jennifer E Towne; James G Krueger
Journal:  Trends Immunol       Date:  2013-01-03       Impact factor: 16.687

5.  Structural and Functional Attributes of the Interleukin-36 Receptor.

Authors:  Guanghui Yi; Joel A Ybe; Siddhartha S Saha; Gary Caviness; Ernest Raymond; Rajkumar Ganesan; M Lamine Mbow; C Cheng Kao
Journal:  J Biol Chem       Date:  2016-06-15       Impact factor: 5.157

6.  IL-36 cytokine expression and its relationship with p38 MAPK and NF-κB pathways in psoriasis vulgaris skin lesions.

Authors:  Qi He; Hong-Xiang Chen; Wen Li; Yan Wu; Shan-Juan Chen; Qing Yue; Min Xiao; Jia-Wen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

7.  IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions.

Authors:  Angelo Massimiliano D'Erme; Dagmar Wilsmann-Theis; Julia Wagenpfeil; Michael Hölzel; Sandra Ferring-Schmitt; Sonja Sternberg; Miriam Wittmann; Bettina Peters; Andreas Bosio; Thomas Bieber; Joerg Wenzel
Journal:  J Invest Dermatol       Date:  2014-12-19       Impact factor: 8.551

8.  IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.

Authors:  Malte Bachmann; Patrick Scheiermann; Lorena Härdle; Josef Pfeilschifter; Heiko Mühl
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

9.  IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-β-Mediated Collagen Expression.

Authors:  Sol Kim; Drake W Williams; Cindy Lee; Terresa Kim; Atsushi Arai; Songtao Shi; Xinmin Li; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  J Bone Miner Res       Date:  2016-10-12       Impact factor: 6.741

10.  IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.

Authors:  Hye-Lin Ha; Hongshan Wang; Prapaporn Pisitkun; Jin-Chul Kim; Ilaria Tassi; Wanhu Tang; Maria I Morasso; Mark C Udey; Ulrich Siebenlist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.